0001104659-22-095769 8-K 16 20220829 5.02 7.01 9.01 20220830 20220830 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 8-K 34 001-39202 221212829 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 8-K 1 tm2224778d1_8k.htm FORM 8-K
0001477845 false 0001477845 2022-08-29 2022-08-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares















Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934


Date of report (Date of earliest event reported): August 29, 2022





(Exact Name of Registrant as Specified in Charter) 


Delaware 001-39202 26-2540421

(State or Other Jurisdiction

of Incorporation)


File Number)

(I.R.S. Employer

Identification No.)


1055 Westlakes Drive, Suite 300
Berwyn, PA 19312

(Address of Principal Executive Offices, and Zip Code)


(610) 727-3913

Registrant’s Telephone Number, Including Area Code


                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock, par value $0.0001 per share ANVS New York Stock Exchange




Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


  ¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


  ¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).


Emerging growth company x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x







Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers


On August 29, 2022, the Board of Directors of Annovis Bio, Inc. (the “Company”) appointed Henry Hagopian III, age 54, as Chief Financial Officer of the Company, effective immediately, to replace Jeffrey McGroarty. Mr. McGroarty will leave the Company to pursue other interests.


Since February 2021, Mr. Hagopian has served as the Senior Vice President, Finance and Treasurer of Organogenesis Holdings, Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused the development, manufacturing and sale of products for the advanced wound care, and surgical and sports medicine market. From October 2007 until January 2021, Mr. Hagopian served in various other positions of increasing responsibility with Organogenesis. Prior to joining Organogenesis, Mr. Hagopian served in various roles in corporate accounting, financial reporting, treasury operations, financial planning & analysis, and investor relations with Circor International, Inc., Stratus Technologies and Lucent Technologies. Mr. Hagopian received both an MBA and an MS in Accounting from the Carroll Graduate School of Management at Boston College and a BS in Economics and Finance, Summa cum laude, from the Silberman College of Business at Farleigh Dickinson University.


In connection with his appointment, on August 29, 2022, the Company entered into an Offer Letter with Mr. Hagopian (the “Offer Letter”), which provides for an annual base salary of $375,000, subject to annual adjustment. Mr. Hagopian will also be eligible for an annual cash incentive bonus based on individual and company-wide performance criteria established by the Compensation Committee of the Company’s Board of Directors. Mr. Hagopian’s target annual cash incentive bonus is 35% of his base salary. For fiscal 2022, Mr. Hagopian will be eligible to receive the full amount of his cash incentive bonus.


Mr. Hagopian will also receive a grant of stock options to purchase 120,000 shares of the Company’s common stock with an exercise price of $11.55. The stock options will vest one-third on the twelve month anniversary of the grant date and the remaining two-thirds will vest in eight consecutive quarterly installments beginning the fifteenth month after August 29, 2022, and will vest in full upon a Change of Control (as defined in the Company’s 2019 Equity Incentive Plan), with vesting conditioned on continued employment on the applicable vesting dates. Mr. Hagopian will also be eligible to participate in all employee benefit plans and programs generally available to the Company’s employees, including the Company’s medical plans, and four weeks of paid time off each year.


In the event Mr. Hagopian’s employment is terminated by the Company for any reason other than Cause (as defined in the Offer Letter), he will be entitled to receive (i) six months of his then-current annual base salary, (ii) either (A) an amount equal to the projected amount of his annual target bonus for the calendar year in which his employment termination occurs, prorated for the number of days he was employed during such calendar year, or (B) if his employment terminates at or within nine months following a Change of Control (as defined in the Company’s 2019 Equity Incentive Plan), an amount equal to the projected amount of his annual target bonus for the calendar year in which his employment termination occurs (without proration), and (iii) continued payment of the employer share of the premium for him to continue participation in the Company’s group health benefits under COBRA until the earlier of six months after his employment termination or the date he is eligible for health benefits through another employer.


The foregoing description of the Offer Letter is a summary only and is qualified in its entirety by reference to the full text of the Offer Letter, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.


There are no transactions between Mr. Hagopian or any member of his immediate family and the Company, or any of its subsidiaries, that would be reportable as a related party transaction under the rules of the Securities and Exchange Commission. In addition, there are no family relationships between Mr. Hagopian and any current director or executive officer of the Company.


Item 7.01 Regulation FD Disclosure


On August 29, 2022, the Company issued a press release announcing the appointment of Mr. Hagopian as Chief Financial Officer of the Company, a copy of which is attached hereto to as Exhibit 99.1.


The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.





Item 9.01 Financial Statements and Exhibits


(d) Exhibits.


The Company hereby files or furnishes, as applicable, the following exhibits:


Exhibit No.   Description
10.1   Offer Letter, dated August 29, 2022, by and between the Company and Henry Hagopian III
99.1   Press Release, dated August 29, 2022 (furnished herewith)
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: August 29, 2022 By:

/s/ Maria Maccecchini

    Name: Maria Maccecchini
    Title: President and Chief Executive Officer





EX-10.1 2 tm2224778d1_ex10-1.htm EXHIBIT 10.1

Exhibit 10.1

Mr. Henry Hagopian, III

56 Robert Road
Stow, MA  01775

Re:            Employment Offer

Dear Henry:

On behalf of Annovis Bio, Inc. (the “Company”), I am pleased to offer you employment as Chief Financial of the Company, reporting to the Company’s Chief Executive Officer or her designee. The purpose of this letter is to set forth the terms of the offer.

1.            Position; Duties.

a.            Your position will be as a full-time employee commencing on August 29, 2022 (the “Commencement Date”). You will work out of the Company’s headquarters in Berwyn, Pennsylvania; provided, however, you may perform your duties for the majority of your business time from your home office or other remote location, provided that you make yourself available for meetings in the Company’s offices and at such other locations as the needs of the Company may from time-to-time require. The Company will reimburse you for your reasonable, documented out-of-pocket costs for traveling from your home to the Company’s offices in accordance with the Company’s standard reimbursement policies.

b.            You agree that, to the best of your ability and experience, you will at all times loyally and conscientiously perform all of the duties and obligations required of and from you consistent with your position and to the reasonable satisfaction of the Company. You will be subject to and expected to abide by the Company’s policies and procedures, as these may be changed by the Company from time to time in its discretion.

2.            Base Salary. You will be paid a base salary at the rate of $375,000 per year (less applicable required withholding and deductions). Your salary will be paid in accordance with the Company’s standard payroll policies. Your performance will be reviewed annually, and your base salary will be considered for upward adjustment accordingly.

3.            Bonus.  You will be eligible for an annual bonus of up to 35% of your annual base salary, including a full (non-prorated) bonus for 2022, based on your performance against corporate and individual objectives.  The Company, in its sole and absolute discretion, will determine whether and to what extent the objectives have been met. Annual bonuses will be paid by March 15th of the year following the year in which the bonus is earned.

p 610.727.39131 f 610.727.4001

1055 Westlakes Drive, Suite 300, Berwyn, PA 10312


4.            Stock Options. Subject to the approval of the Board of Directors, promptly after the Commencement Date, you will be granted a stock option to purchase 120,000 shares of the Company’s common stock under the Company’s 2019 Equity Incentive Plan (the “Equity Plan”).  The per-share exercise price of the stock option will be the fair market value on the date of grant, as determined in accordance with the Equity Plan.  The stock option will vest as follows: one-third will vest twelve months after the Commencement Date and the remaining two-thirds will vest in eight consecutive quarterly installments beginning the fifteenth month after the Commencement Date and will vest in fully upon a Change of Control (as defined in the Equity Plan), provided that you continue to be employed by the Company on each respective vesting date.  In addition, you will be eligible to participate in the future in equity incentive programs established by the Company in accordance with the terms of those programs, and the Board will consider an additional stock option grant to you on an annual basis in an amount commensurate with published benchmarks for companies comparable to the Company.  Each stock option will be subject to the terms of the Equity Plan and a stock option agreement to be executed by you as a condition to the grant.

5.            Employee Benefits. You will be entitled to receive four weeks of paid time off each year and to participate in the Company’s other employee benefit plans as they are generally made available to other employees of similar status and service.

These benefits, as well as all other Company compensation and benefit programs, are subject to change from time to time as deemed appropriate by the Company in its sole discretion.

6.            Employee Covenants. As a condition of employment, you will be required to sign the Company’s form of Employee Confidential Disclosure, Invention Assignment, Non-Competition, Non-Solicitation and Non-Interference Agreement (the “Confidential Disclosure Agreement”). By accepting this offer, you agree that you will not bring with you to the Company or use in any way during your employment with the Company, any confidential information, trade secrets or proprietary materials or processes of any former employer, entity, trust or individual for which you have performed services. You further confirm that by accepting this offer you will not breach any contract, agreement, or other instrument to which you are a party or are bound.


7.            At-Will Employment; Employment Termination.

a.,            Please note that this letter and your response do not create a contract or promise of employment for a definite period of time.  Therefore, your employment will be on an “at-will” basis, meaning it may be terminated by either party at any time, with or without cause.  We do request, however, that you give reasonable notice if you decide to terminate your employment with us. In the event that you become an employee of the Company pursuant to this letter and the Company thereafter terminates your employment for any reason other than Cause (as defined below), then, subject to the condition precedent of your execution and delivery of a general release of claims satisfactory to the Company to be delivered to you at the time of your termination and returning to the Company all of its property and confidential information in your possession, you will be entitled to a severance payment in an aggregate amount (less required withholding and deductions) equal to (a) six months (your “Severance Period”) of your then base salary, (b) either (i) an amount equal to the projected amount of your annual target bonus for the calendar year in which your employment termination occurs, prorated for the number of days you are employed during such calendar year, but payable only if and to the extent the Board determines whether and to what extent the applicable corporate and individual objectives for such calendar year have been met; or (ii) if your employment terminates at the time of or within nine months following a Change in Control, an amount equal to the projected amount of your annual target bonus for such calendar year without proration for the number of days you are employed during such calendar year, and (c) if timely elected, continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. §1161 et seq., commonly known as “COBRA,” with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of: (i) the end of your Severance Period, and (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA. Subject to the provisions of Section 9.a., any severance payments due hereunder shall commence as soon as administratively feasible within 60 days after your termination of employment provided you have timely executed and returned the release and, if a revocation period is applicable, you have not revoked the release; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the severance payments shall begin to be paid in the second calendar year. The severance will be payable in six monthly installments over a period of six months unless your employment terminates at the time of or within nine months following a Change in Control, in which case, the severance will be payable in a single lump sum payment.

b.            For purposes of this letter, “Cause” means (i) your continued failure to substantially perform your duties and obligations to the Company, including but not limited to any material breach of this letter and/or the Confidential Disclosure Agreement or any material violation of the Company’s written policies or rules your fiduciary duties to the Company, and, if capable of cure, your failure to cure the same within 30 business days after being notified by the Company; (ii) your having committed an act of willful fraud, material dishonesty or willful misconduct that involves or reflects adversely on the Company; or (iii) your having been indicted for, convicted of or pleaded nolo contendere with respect to a felony involving moral turpitude.

8.            Parachute Provisions. If the Company determines in good faith that any payments or benefits provided to you constitute “parachute payments” within the meaning of Section 280G of the Code (“Parachute Payments”) and may be subject to an excise tax imposed pursuant to Section 4999 of the Code, the Parachute Payments will be reduced to an amount determined by the Company in good faith to be the maximum amount that may be provided to you without resulting in any portion of such Parachute Payments being subject to such excise tax (the amount of such reduction, the “Cutback Benefits”). You will be entitled to select which Parachute Payments (of those that are not considered to be deferred compensation under Section 409A of the Code) shall be reduced hereunder. If the Company is then eligible, the Company will use reasonable efforts to obtain the approval of the Cutback Benefits by the Company’s stockholders in the manner contemplated by Q&A 7 of Treas. Reg. Section 1.280G, it being understood and agreed that the Company does not guarantee that such approval will be obtained. If, and only if, the Company determines that such approval is obtained, will you be entitled to receive the Cutback Benefits without regard to the first sentence of this Section.



9.            Section 409A. This section is intended to help ensure that compensation paid or delivered to you pursuant to this letter agreement either is paid in compliance with, or is exempt from, Section 409A of the Internal Revenue Code of 1986, as amended and the rules and regulations promulgated thereunder (collectively, “Section 409A”):

a.            Any taxable reimbursement of business or other expenses, or any provision of taxable in-kind benefits to you, as specified under this letter agreement, shall be subject to the following conditions: (i) the expenses eligible for reimbursement or the amount of in-kind benefits provided in one taxable year shall not affect the expenses eligible for reimbursement or the amount of in-kind benefits provided in any other taxable year; (ii) the reimbursement of an eligible expense shall be made no later than the end of the year after the year in which such expense was incurred; and (iii) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit. Any reimbursement of taxes, as specified under this letter agreement, shall be paid in any event not later than the end of your taxable year next following the taxable year in which you remit the applicable taxes to the appropriate taxing authority.

b.            The payment of any amounts otherwise payable to you on account of termination of employment under this letter agreement that constitute deferred compensation within the meaning of Section 409A and that are subject (among other conditions, if any) to a release of claims may be delayed at the discretion of the Company for up to 90 days following your termination of employment (without regard to when your release is delivered and becomes irrevocable (an “Effective Release”) if reasonably determined by the Company to be necessary to avoid penalties under Section 409A). Regardless of any payment, however, all such amounts remain conditioned on an Effective Release such that if you fail to deliver (or revoke) your release you will forfeit and must immediately return such amounts on the Company’s demand.

c.            In applying Section 409A to compensation paid pursuant to this letter agreement, any right to a series of installment payments under this letter agreement shall be treated as a right to a series of separate payments.

You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company, or the Board related to tax liabilities arising from your compensation provided that the Company complies with the terms and provisions of this letter other than with respect to the Company’s failure to comply with the terms and provisions of this letter.

10.           Additional Agreements.

a.            You will be subject to and expected to abide by the Company’s policies and procedures, as these may be changed from time to time.

b.            This offer expires at 5:00 p.m. on August 29, 2022, if not accepted by then.

c.            Your employment by the Company will be subject to successful completion of a pre-employment background check and documentation of eligibility to work in the United States, to be completed no later than three business days following the Commencement Date.


d.            You will be entitled to defense and indemnification for your actions or omissions taken on behalf of the Company in your capacity as Chief Financial Officer or other authorized role to the fullest extent permitted by applicable law and the Company’s Certificate of Incorporation and By-Laws.

e.            The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance, or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed by the laws of the Commonwealth of Pennsylvania, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Pennsylvania in connection with any Dispute or any claim related to any Dispute.

11.           Assignment. Neither you nor the Company may make any assignment of this letter agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this letter agreement (including, without limitation, the Confidential Disclosure Agreement) without your consent to an affiliate or to any person with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This letter agreement shall inure to the benefit of and be binding upon you and the Company, and each of its respective successors, executors, administrators, heirs and permitted assigns.

12.           Counterparts; Electronic or Facsimile Transmission. This letter agreement may be executed in one or more counterparts, both of which shall be considered one and the same agreement and shall become a binding agreement when one or more counterparts have been signed by each party and delivered to the other party. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.

(Signature page follows.)


To indicate your acceptance of this letter agreement, please sign and date this letter agreement in the spaces provided below. Again, let me indicate how pleased we all are to extend this offer and how much we look forward to working with you.

By: /s/ Maria L. Maccecchini
Maria L. Maccecchini
President and CEO

Accepted and agreed:

/s/ Henry Hagopian, III

Henry Hagopian, III

Date: August 29, 2022


EX-99.1 3 tm2224778d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1



Annovis Bio Appoints Henry Hagopian III as Chief Financial Officer


BERWYN, PA., Aug. 29, 2022 /PRNewswire/ -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a clinical-stage drug platform company addressing neurodegenerative diseases, announced the appointment of Henry Hagopian III as Chief Financial Officer, effective immediately.  Mr. Hagopian comes to Annovis with 30 years of finance and accounting experience, including 15 years of increasing responsibility at Organogenesis, a leading publicly-traded regenerative medicine company.  The company has also announced that Jeff McGroarty has stepped away from his role as Chief Financial Officer to pursue other interests.  Mr. McGroarty will assist in an orderly transition of his duties over the next several weeks.


“The company has made substantial progress and is now reaching an exciting inflection point given the advancement of buntanetap into Phase 3 clinical trials,” said Maria L. Maccecchini, Ph.D., Founder, President, and CEO of Annovis.  “Looking at the future of Annovis, Henry is an excellent addition to our team and will help take the company to the next level given his extensive experience in finance, accounting and strategic execution. I look forward to working closely with him to advance our mission of revolutionizing the treatment of neurodegenerative diseases.”


“This is an exciting moment to be joining Annovis as it continues its mission to improve the lives of those suffering from neurodegenerative disorders,” said Mr. Hagopian. “I’m excited to join this dynamic and talented team and look forward to working with the management to advance the pipeline and contribute to its success. I share the management team’s passion to advance buntanetap forward, having experienced the devastating effects of neuro degenerative disease in my own family and among close friends.”


Mr. Hagopian joins Annovis from Organogenesis, a Nasdaq-listed leading regenerative medicine company, where he spent 15 years of increasing responsibility, most recently as Senior Vice President, Finance and Treasurer.  In 2020, he was the company’s interim Chief Financial Officer. Mr. Hagopian has an extensive background in corporate accounting, financial reporting, treasury operations, financial planning & analysis (FP&A), and investor relations.


Mr. Hagopian received both an MBA and an MS in Accounting from the Carroll Graduate School of Management at Boston College and a BS in Economics and Finance, Summa cum laude, from the Silberman College of Business at Farleigh Dickinson University.


About Annovis Bio, Inc.


Headquartered in Berwyn, Pennsylvania, Annovis Bio, Inc. is a clinical-stage, drug platform company developing transformative therapies that treat neurodegenerative disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and other chronic and acute neurodegenerative diseases. The Company believes that it is the only company developing a drug that inhibits more than one neurotoxic protein, improves the information highway of the nerve cell, known as axonal transport, reduces inflammation and protects nerve cells from dying in chronic and acute neurodegeneration. Annovis conducted two Phase 2 studies: one in AD patients and one in both AD and PD patients. In the AD/PD study, buntanetap showed improvements in cognition and memory in AD as well as body and brain function in PD patients.





For more information on Annovis Bio, please visit the Company’s website www.annovisbio.com and follow us on LinkedIn and Twitter.


Forward-Looking Statements


Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words, and include, without limitation, statements regarding the timing, effectiveness, and anticipated results of buntanetap clinical trials. Forward-looking statements are based on Annovis Bio, Inc.’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully in the section titled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and Annovis Bio, Inc. undertakes no duty to update such information except as required under applicable law.




Media and Investor Contact:


Nic Johnson

Russo Partners, LLC

(303) 482-6405





EX-101.SCH 4 anvs-20220829.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 anvs-20220829_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 anvs-20220829_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 tm2224778d1_ex10-1img001.jpg GRAPHIC begin 644 tm2224778d1_ex10-1img001.jpg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end GRAPHIC 8 tm2224778d1_ex99-1img001.jpg GRAPHIC begin 644 tm2224778d1_ex99-1img001.jpg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end XML 9 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Aug. 29, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 29, 2022
Entity File Number 001-39202
Entity Registrant Name ANNOVIS BIO, INC.
Entity Central Index Key 0001477845
Entity Tax Identification Number 26-2540421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1055 Westlakes Drive
Entity Address, Address Line Two Suite 300
Entity Address, City or Town Berwyn
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19312
City Area Code 610
Local Phone Number 727-3913
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol ANVS
Security Exchange Name NYSE
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period true
XML 10 tm2224778d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001477845 2022-08-29 2022-08-29 iso4217:USD shares iso4217:USD shares 0001477845 false 8-K 2022-08-29 ANNOVIS BIO, INC. DE 001-39202 26-2540421 1055 Westlakes Drive Suite 300 Berwyn PA 19312 610 727-3913 Common Stock, par value $0.0001 per share ANVS NYSE false false false false true true EXCEL 11 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 12 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 13 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://annovisbio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports tm2224778d1_8k.htm anvs-20220829.xsd anvs-20220829_lab.xml anvs-20220829_pre.xml tm2224778d1_ex10-1.htm tm2224778d1_ex99-1.htm http://xbrl.sec.gov/dei/2021q4 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "tm2224778d1_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "tm2224778d1_8k.htm" ] }, "labelLink": { "local": [ "anvs-20220829_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20220829_pre.xml" ] }, "schema": { "local": [ "anvs-20220829.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021q4": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ANVS", "nsuri": "http://annovisbio.com/20220829", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2224778d1_8k.htm", "contextRef": "From2022-08-29to2022-08-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://annovisbio.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "tm2224778d1_8k.htm", "contextRef": "From2022-08-29to2022-08-29", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021q4", "presentation": [ "http://annovisbio.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 17 0001104659-22-095769-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-22-095769-xbrl.zip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

#@ 86YV&UL4$L! A0#% @ )S > M596T>X(K&P '98 !( ( !)Q8 '1M,C(R-##$P+3$N:'1M4$L! A0#% @ )S >54/9 MY[OL"P W2@ !8 ( !H4X '1M,C(R-#